



## For Health Professionals Who Care For Cancer Patients

### Inside This Issue:

- **Editor's Choice** – New Programs: Maintenance Bortezomib for Multiple Myeloma (UMYBORMTN)
- **Drug Update** – Letter to Physicians: Warfarin Monitoring in Patients on GI Capecitabine Protocols
- **Cancer Drug Manual** – Revised: Anagrelide, Gefitinib, Ipilimumab, Nivolumab
- **Benefit Drug List** – New: UMYBORMTN
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UMYBORMTN, USMAVFIPI; Revised: BRLATWAC, GOOVAI, GOOVADR, GOOVIPPC, GOOVPLDC, GOOVTAM, UMYLENDEX, UMYLENMTN, USMAVFIPI, USMAVIPI; List of revised GI protocols with updated information on capecitabine and fluorouracil associated diarrhea: GIAJCAP, GIAJCAPOX, GIAJFFOX, GIAJFL, GIAVCAP, GIAVFL, GIAVTZCAP, GICAPOX, GICART, UGICOXB, GICPART, GIEFUPRT, UGIFFOXB, GIFOLFOX, GIFUART, GIFUC, GIFUFA, GIFUIP, GIFUPART, GIGAIRT, GIGAJCC, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVECC, GIGAVECF, GIGECC, GIGECF, GIHIPEC, GIRAJCOX, GIRAJFFOX, GIRCAP, GIRCRT, GIRINFRT
- **Website Resources and Contact Information**

## EDITOR'S CHOICE

### NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective 1 November 2015:

#### Lymphoma/Multiple Myeloma:

**Bortezomib Maintenance for Multiple Myeloma (UMYBORMTN)** – Bortezomib offers an alternative to the currently funded lenalidomide maintenance therapy (UMYLENMTN) for high-risk multiple myeloma after stem cell transplant. Patients must have confirmed chromosomal abnormalities of del (17p) or t(4;14). In a subset analysis of a phase III trial, maintenance bortezomib post-transplant was associated with increased progression free survival (26.2 vs. 12.0 months). At the BC Cancer Agency, bortezomib is the preferred agent for patients with these high-risk chromosomal abnormalities, but lenalidomide remains an option recognizing the convenience of oral therapies.

#### Reference:

K Neben, HM Lohhorst, A Jauch, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119(4):940-948.

## DRUG UPDATE

### LETTER TO PHYSICIANS: WARFARIN MONITORING IN PATIENTS ON GI CAPECITABINE PROTOCOLS

A “Warfarin Monitoring Letter” to physicians will be available on the BCCA website with all the Gastrointestinal Protocols containing capecitabine. Capecitabine can reduce the metabolism of warfarin through inhibition of the cytochrome P450 2C9 enzyme. Increased INR monitoring may be required in patients treated with concurrent capecitabine and warfarin therapies.

Large INR changes and severe bleeding have been reported. These effects have been seen days to months after initiating capecitabine as well as within 1 month of stopping capecitabine. Therefore, it is important that non-BCCA physicians who prescribe warfarin are aware of the increased risk and monitoring required for patients treated concurrently with capecitabine. The letter shall be given to patients receiving a GI capecitabine regimen to bring to their family physician.

## CANCER DRUG MANUAL

### REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

#### **Anagrelide Monograph and Patient Handout**

- Monograph – addition of *Side Effects* paragraphs for cardiovascular effects, hepatic metabolism, interstitial lung diseases, platelet counts, and renal abnormalities
- Patient Handout – added information on QT-prolongation

#### **Gefitinib Patient Handout**

- Administration instructions have been updated to delete the requirement for morning administration as per current product information. Patients are now instructed that gefitinib can be taken with food or on an empty stomach, and should be taken about the same time each day.

#### **Ipilimumab Monograph and Patient Handout**

- Monograph – Thirty minute infusions: new paragraph added to *Side Effects* section and *Parenteral Administration* table updated. The frequency of reported infusion reactions may be slightly increased when ipilimumab is infused over 30 minutes (instead of the standard 90 minutes). As infusion reactions are reported with the second dose of ipilimumab, the infusion time should be reduced only if the patient has no reaction with cycle 2. Please refer to protocol for more details.
- Handout – In the *Management* section for skin rashes, the patient is now directed to follow standard guidelines regarding sunscreen use and sun protection as per [recommendations](#) from the American Society of Clinical Oncology (ASCO).

#### **Nivolumab Interim Monograph and CPSC**

- Updated information on the Canadian supplier, and that a Notice of Compliance has been granted

## BENEFIT DRUG LIST

### NEW PROGRAMS

The following program has been added to the [Benefit Drug List](#) effective 1 November 2015:

Protocol Title	Protocol Code	Benefit Status
Maintenance Therapy for Multiple Myeloma using <b>Bortezomib</b> for Patients with the High-Risk Chromosome Abnormality	UMYBORMTN	Restricted

## LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

### NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UMYBORMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Maintenance Therapy for Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality
USMAVFIPI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

### REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRLATWAC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Cycle-specific information added</i>	NEOAdjuvant Therapy for Locally Advanced Breast Cancer Using Weekly PAClitaxel Followed by DOXOrubicin and Cyclophosphamide
GOOVAI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy for Advanced Ovarian Cancer Using an Aromatase Inhibitor
GOOVADR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Second Line Treatment Using DOCetaxel and CARBOplatin for Epithelial Ovarian Cancer Relapsing after Primary Treatment

**REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GOOVIPPC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Primary Treatment of Stage III less than or equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage 1 Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer Using Intravenous and Intraperitoneal PACLitaxel and Intraperitoneal CARBOplatin
GOOVPLDC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Second Line Treatment for Epithelial Ovarian Cancer Relapsing After Primary Treatment Using Pegylated Liposomal DOXOrubicin (PLD) and CARBOplatin
GOOVTAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy for Advanced Ovarian Cancer Using Tamoxifen
UMYLENDEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor misspelling corrected under Tests</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone
UMYLENMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modification in renal dysfunction clarified, minor misspelling corrected under Tests</i>	Maintenance Therapy of Multiple Myeloma Using Lenalidomide
USMAVFIPI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Infusion time and toxicities management updated</i>	First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
USMAVIPI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Infusion time and toxicities management updated</i>	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

The following gastrointestinal protocols containing fluorouracil and capecitabine have been updated to include more information on the monitoring and management of drug-associated diarrhea, as well as the potential increased risk in patients with DPD deficiency.

CODE	Protocol Title
GIAJCAP	Adjuvant Therapy of Colon Cancer Using Capecitabine
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIAJFL	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVCAP	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
GIAVFL	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVTZCAP	Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
GICART	Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy

<b>CODE</b>	<b>Protocol Title</b>
<b>UGICOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
<b>GICPART</b>	Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy
<b>GIEFUPRT</b>	Combined Modality Therapy for Locally Advanced esophageal Cancer Using Fluorouracil and CISplatin
<b>UGIFFOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
<b>GIFOLFOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
<b>GIFUART</b>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using Mitomycin, Fluorouracil and Radiation Therapy
<b>GIFUC</b>	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer Using Infusional Fluorouracil and CISplatin
<b>GIFUFA</b>	Palliative Therapy for Advanced Colorectal Cancer Using Leucovorin and Fluorouracil
<b>GIFUIP</b>	Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil
<b>GIFUPART</b>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using CISplatin, Infusional Fluorouracil and Radiation Therapy
<b>GIGAIRT</b>	Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma Using Fluorouracil and Folinic Acid (Leucovorin) and Radiation Therapy
<b>GIGAJCC</b>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation, Using CISplatin and Capecitabine
<b>GIGAJCPR</b>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy
<b>GIGAVCC</b>	Palliative Therapy for Metastatic or Locally Advanced Gastric Cancer Using CISplatin and Capecitabine
<b>GIGAVCCT</b>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Capecitabine and Trastuzumab
<b>GIGAVCFT</b>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab
<b>GIGAVECC</b>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine
<b>GIGAVECF</b>	Palliative Therapy for Metastatic or Locally Advanced Gastric, Esophagogastric Cancer Using Epirubicin, CISplatin and Infusional Fluorouracil
<b>GIGECC</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Capecitabine
<b>GIGECF</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Infusional Fluorouracil
<b>GIHIPEC</b>	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Peritoneal Carcinomatosis from Limited Advanced Colorectal and Appendiceal Carcinomas Using Oxaliplatin and Fluorouracil (5-FU)
<b>GIRAJCOX</b>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
<b>GIRAJFFOX</b>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
<b>GIRCAP</b>	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine
<b>GIRCRT</b>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy
<b>GIRINFRT</b>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy

## WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>
Systemic Therapy Update	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update</a>
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
Cancer Drug Manual	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual</a>
Cancer Management Guidelines	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines</a>
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols">www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols</a>
Systemic Therapy Program Policies	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
CON Pharmacy Educators	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy">www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy</a>

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

## EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)  
 Mário de Lemos, PharmD, MSc (Oncol)  
 Caroline Lohrisch, MD  
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS  
 Ava Hatcher, RN  
 Rob Watt, BSc(Pharm)